Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print January 25, 2008, 10.1148/radiol.2463070962
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Movies and Supplemental Figures
Right arrow All Versions of this Article:
2463070962v1
246/3/734    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Sevick-Muraca, E. M.
Right arrow Articles by Mawad, M. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sevick-Muraca, E. M.
Right arrow Articles by Mawad, M. E.
(Radiology 2008;246:734-741.)
© RSNA, 2008


Breast Imaging

Imaging of Lymph Flow in Breast Cancer Patients after Microdose Administration of a Near-Infrared Fluorophore: Feasibility Study1

Eva M. Sevick-Muraca, PhD, Ruchi Sharma, ME, John C. Rasmussen, PhD, Milton V. Marshall, PhD, Juliet A. Wendt, MD, Hoang Q. Pham, MD, Elizabeth Bonefas, MD, Jessica P. Houston, PhD, Lakshmi Sampath, MS, Kristen E. Adams, PhD, Darlene Kay Blanchard, PhD, MD, Ronald E. Fisher, MD, PhD, Stephen B. Chiang, MD, Richard Elledge, MD, and Michel E. Mawad, MD

1 From the Department of Radiology, Division of Molecular Imaging, Baylor College of Medicine, One Baylor Plaza, BCM 360, Houston, TX 77030 (E.M.S., R.S., J.C.R., M.V.M., J.A.W., H.Q.P., E.B., J.P.H., L.S., K.E.A., D.K.B., R.E.F., R.E., M.E.M.); and Department of Radiology, the Methodist Hospital, Houston, Tex (S.B.C.). Received June 4, 2007; revision requested August 1; revision received August 17; accepted August 28; final version accepted October 8. Supported in part by National Cancer Institute grant R01 CA112679, the American Cancer Society (RSG-06-213-01-LR), and Becton-Dickinson Technologies. Address correspondence to E.M.S. (e-mail: evas{at}bcm.tmc.edu).

Purpose: To prospectively demonstrate the feasibility of using indocyanine green, a near-infrared (NIR) fluorophore at the minimum dose needed for noninvasive optical imaging of lymph nodes (LNs) in breast cancer patients undergoing sentinel lymph node mapping (SLNM).

Materials and Methods: Informed consent was obtained from 24 women (age range, 30–85 years) who received intradermal subcutaneous injections of 0.31–100 µg indocyanine green in the breast in this IRB-approved, HIPAA-compliant, dose escalation study to find the minimum microdose for imaging. The breast, axilla, and sternum were illuminated with NIR light and the fluorescence generated in the tissue was collected with an NIR-sensitive intensified charged-coupled device. Lymphoscintigraphy was also performed. Resected LNs were evaluated for the presence of radioactivity, blue dye accumulation, and fluorescence. The associations between the resected LNs that were fluorescent and (a) the time elapsed between NIR fluorophore administration and resection and (b) the dosage of NIR fluorophores were tested with the Spearman rank and Pearson product moment correlation tests, respectively.

Results: Lymph imaging consistently failed with indocyanine green microdosages between 0.31 and 0.77 µg. When indocyanine green dosages were 10 µg or higher, lymph drainage pathways from the injection site to LNs were imaged in eight of nine women; lymph propulsion was observed in seven of those eight. When propulsion in the breast and axilla regions was present, the mean apparent velocities ranged from 0.08 to 0.32 cm/sec, the time elapsed between "packets" of propelled fluid varied from 14 to 92 seconds. In patients who received 10 µg of indocyanine green or more, a weak negative correlation between the fluorescence status of resected LNs and the time between NIR fluorophore administration and LN resection was found. No statistical association was found between the fluorescence status of resected LNs and the dose of NIR fluorophore.

Conclusion: NIR fluorescence imaging of lymph function and LNs is feasible in humans at microdoses that would be needed for future molecular imaging of cancer-positive LNs.

Supplemental material: http://radiology.rsnajnls.org/cgi/content/full/2463070962/DC1

© RSNA, 2008




This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
R. SHARMA, J. A. WENDT, J. C. RASMUSSEN, K. E. ADAMS, M. V. MARSHALL, and E. M. SEVICK-MURACA
New Horizons for Imaging Lymphatic Function
Ann. N.Y. Acad. Sci., May 1, 2008; 1131(1): 13 - 36.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2008 by the Radiological Society of North America.